Nicardipine Laboratoire Aguettant (Nicardipine Hydrochloride)

Nicardipine Hydrochloride, the active ingredient in Nicardipine Laboratoire Aguettant, is a dihydropyridine calcium channel blocker presented as an intravenous solution for intravenous administration. It is used to lower elevated blood pressure and relieve chest pain caused by angina pectoris in adult patients. It is administered under medical supervision in acute care settings.

GNH USA supplies Nicardipine Laboratoire Aguettant as a licensed, Good Distribution Practice‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies and clinics worldwide with consistent quality and regulatory assurance, and supports therapeutic protocols across diverse healthcare systems.

Nicardipine is a calcium channel blocker that acts on vascular smooth muscle to manage cardiovascular conditions.

- Hypertension: reduces systemic vascular resistance and lowers blood pressure. - Angina pectoris: improves coronary blood flow and alleviates chest pain. - Hypertensive emergency: provides rapid blood pressure control in critical care settings.

Intravenous nicardipine may be associated with several adverse reactions, which are categorized by frequency.

Common Side Effects: - Headache - Flushing - Reflex tachycardia - Nausea

Serious or Rare Side Effects: - Severe hypotension - Myocardial infarction - Atrioventricular block

When using nicardipine, clinicians should observe several safety measures.

- Blood pressure monitoring: check frequently during infusion. - Cardiac function assessment: evaluate for ischemia or heart block. - Hepatic impairment: dose may need adjustment. - Avoid rapid infusion: administer at recommended rate to prevent abrupt hypotension. - Contraindicated in known hypersensitivity: discontinue if allergic reaction occurs. - Store at room temperature: keep in original container, protect from moisture and light.

Nicardipine can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Concomitant potent vasodilators: may cause excessive hypotension. - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase nicardipine plasma levels. - Other calcium‑channel blockers: additive blood‑pressure lowering effect.

Moderate Interactions (Monitor Closely):\n- CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce therapeutic effect. - Diuretics: can enhance hypotensive response. - NSAIDs: may attenuate antihypertensive efficacy.